Repository logo
 

Effect of Disease Activity at Three and Six Months After Diagnosis on Long-Term Outcomes in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

Simple item page
cam.issuedOnline2019-03-28
dc.contributor.authorGopaluni, Seerapani
dc.contributor.authorFlossmann, Oliver
dc.contributor.authorLittle, Mark A
dc.contributor.authorO'Hara, Paul
dc.contributor.authorBekker, Pirow
dc.contributor.authorJayne, David
dc.contributor.authorEuropean Vasculitis Society
dc.contributor.orcidGopaluni, Seerapani [0000-0002-1584-6186]
dc.date.accessioned2018-12-14T00:30:37Z
dc.date.available2018-12-14T00:30:37Z
dc.date.issued2019-05
dc.description.abstractOBJECTIVE: The treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) aims to suppress disease activity and prevent subsequent disease flare. This study sought to explore the association of early disease control with long-term outcomes to validate early disease control as an end point for future clinical trials in AAV. METHODS: Data from 4 European Vasculitis Society inception clinical trials in AAV (1995-2002) and subsequent data on long-term outcomes from the trial data registry were studied. Clinical parameters in patients with AAV at baseline and at 3 and 6 months after diagnosis were assessed to study the long-term risk of death and end-stage renal failure (ESRF). At 6 months, outcomes were defined based on a disease status of either sustained remission (remission by 3 months, sustained to 6 months), late remission (remission after 3 months and by 6 months), relapsing disease (remission by 3 months but relapse by 6 months), or refractory disease (no remission by 6 months). RESULTS: Of the 354 patients with AAV who were followed up for a median of 5.7 years, 46 (13%) developed ESRF, 66 (18.6%) died, and 89 (25.1%) had either died or developed ESRF. At 6 months, predictors of the composite end point of death or ESRF were as follows: age (hazard ratio [HR] 1.02, 95% confidence interval [95% CI] 1-1.05; P = 0.012), estimated glomerular filtration rate (HR 0.94, 95% CI 0.92-0.95; P < 0.001), and disease status at 6 months (late remission, HR 2.94, 95% CI 1.1-7.85 [P = 0.031]; relapsing disease, HR 8.21, 95% CI 2.73-24.65 [P < 0.001]; refractory disease, HR 4.89, 95% CI 1.96-12.18 [P = 0.001]). Similar results were observed when these analyses were performed separately for death and for ESRF. CONCLUSION: The results of this study suggest that disease status at 3 and 6 months following the diagnosis of AAV may be predictive of the long-term risk of mortality and ESRF, and therefore these may be valid end points for induction trials in AAV. The current findings need to be validated in a larger data set.
dc.format.mediumPrint-Electronic
dc.identifier.doi10.17863/CAM.34197
dc.identifier.eissn2326-5205
dc.identifier.issn2326-5191
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/286888
dc.languageeng
dc.language.isoeng
dc.publisherWiley
dc.publisher.urlhttp://dx.doi.org/10.1002/art.40776
dc.subjectAdult
dc.subjectAge Factors
dc.subjectAged
dc.subjectAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
dc.subjectFemale
dc.subjectGlomerular Filtration Rate
dc.subjectHumans
dc.subjectImmunosuppressive Agents
dc.subjectKidney Failure, Chronic
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectMortality
dc.subjectPlasma Exchange
dc.subjectPrognosis
dc.subjectProportional Hazards Models
dc.subjectRecurrence
dc.subjectRemission Induction
dc.subjectSeverity of Illness Index
dc.titleEffect of Disease Activity at Three and Six Months After Diagnosis on Long-Term Outcomes in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
dc.typeArticle
dcterms.dateAccepted2018-11-06
prism.endingPage791
prism.issueIdentifier5
prism.publicationDate2019
prism.publicationNameArthritis Rheumatol
prism.startingPage784
prism.volume71
pubs.funder-project-idCambridge University Hospitals NHS Foundation Trust (CUH) (3819-1617-16)
rioxxterms.licenseref.startdate2019-05
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.typeJournal Article/Review
rioxxterms.versionAM
rioxxterms.versionofrecord10.1002/art.40776

Files

Original bundle
Now showing 1 - 3 of 3
No Thumbnail Available
Name:
Main_document_clean_final.docx
Size:
51.71 KB
Format:
Microsoft Word XML
Description:
Accepted version
Licence
http://www.rioxx.net/licenses/all-rights-reserved
Download
No Thumbnail Available
Name:
Tables_20180918.docx
Size:
28.22 KB
Format:
Unknown data format
Description:
Supporting information
Licence
http://www.rioxx.net/licenses/all-rights-reserved
Download
Thumbnail Image
Name:
Figure_1.2.pdf
Size:
1.41 MB
Format:
Adobe Portable Document Format
Description:
Supporting information
Licence
http://www.rioxx.net/licenses/all-rights-reserved
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
DepositLicenceAgreementv2.1.pdf
Size:
150.9 KB
Format:
Adobe Portable Document Format
Download

Collections

University of Cambridge Research Outputs (Articles and Conferences)